Recent advances in managing chronic HCV infection: Focus on therapy in patients with severe liver disease

F1000Research

Volumn 5, Issue , 2016, Pages

  Maan, Raoel ^a   van der Meer, Adriaan J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALISPORIVIR; BOCEPREVIR; DACLATASVIR; DASABUVIR; DASATINIB; ERLOTINIB; LEDIPASVIR; OMBITASVIR; PARITAPREVIR; PEGINTERFERON ALPHA; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; VELPATASVIR;

ACUTE CORONARY SYNDROME; ADAPTIVE IMMUNITY; ANTIVIRAL THERAPY; BRAIN ISCHEMIA; CAUSE OF DEATH; CHRONIC HEPATITIS C; COHORT ANALYSIS; COMORBIDITY; COMPENSATED LIVER CIRRHOSIS; CYTOPENIA; DECOMPENSATED LIVER CIRRHOSIS; DEPRESSION; DETERIORATION; DIABETES MELLITUS; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; END STAGE RENAL DISEASE; FLU LIKE SYNDROME; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HOSPITALIZATION; HUMAN; IN VITRO STUDY; INNATE IMMUNITY; LIVER FIBROSIS; LIVER TRANSPLANTATION; LYMPHOMA; META ANALYSIS (TOPIC); MODEL FOR END STAGE LIVER DISEASE SCORE; MORBIDITY; MORTALITY; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); REVIEW; RISK FACTOR; SUSTAINED VIROLOGICAL RESPONSE; TOXIC HEPATITIS; TREATMENT DURATION; VIRAL CLEARANCE; VIRUS REPLICATION;

EID: 84964570059     PISSN: 20461402     EISSN: 1759796X     Source Type: Journal    
DOI: 10.12688/f1000research.7399.1     Document Type: Review

References (99)

1. Gower E Estes C Blach S: Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(1 Suppl):S45-57. 25086286 10.1016/j.jhep.2014.07.027 F1000 Recommendation
2. Hajarizadeh B Grebely J Dore GJ: Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013;10(9):553-562. 23817321 10.1038/nrgastro.2013.107
3. Thein HH Yi Q Dore GJ: Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 2008;48(2):418-431. 18563841 10.1002/hep.22375
4. Davis GL Alter MJ El-Serag H: Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138(2):513-21, 521.e1-6. 19861128 10.1053/j.gastro.2009.09.067
5. Messina JP Humphreys I Flaxman A: Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61(1):77-87. 25069599 10.1002/hep.27259 4303918
6. von Wagner M Lee JH Kronenberger B: Impaired health-related quality of life in patients with chronic hepatitis C and persistently normal aminotransferase levels. J Viral Hepat. 2006;13(12):828-834. 17109682 10.1111/j.1365-2893.2006.00772.x
7. Teuber G Schäfer A Rimpel J: Deterioration of health-related quality of life and fatigue in patients with chronic hepatitis C: Association with demographic factors, inflammatory activity, and degree of fibrosis. J Hepatol. 2008;49(6):923-929. 18929420 10.1016/j.jhep.2008.07.025
8. Sarkar S Jiang Z Evon DM: Fatigue before, during and after antiviral therapy of chronic hepatitis C: results from the Virahep-C study. J Hepatol. 2012;57(5):946-952. 22760009 10.1016/j.jhep.2012.06.030 3477271
9. Jacobson IM Cacoub P Dal Maso L: Manifestations of chronic hepatitis C virus infection beyond the liver. Clin Gastroenterol Hepatol. 2010;8(12):1017-1029. 20870037 10.1016/j.cgh.2010.08.026
10. Lee MH Yang HI Lu SN: Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis. 2012;206(4):469-477. 22811301 10.1093/infdis/jis385 F1000 Recommendation
11. Vezali E Aghemo A Colombo M: A review of the treatment of chronic hepatitis C virus infection in cirrhosis. Clin Ther. 2010;32(13):2117-2138. 21316532 10.1016/S0149-2918(11)00022-1
12. Swain MG Lai MY Shiffman ML: A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology. 2010;139(5):1593-1601. 20637202 10.1053/j.gastro.2010.07.009 F1000 Recommendation
13. Bacon BR Gordon SC Lawitz E: Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1207-1217. 21449784 10.1056/NEJMoa1009482 3153125 F1000 Recommendation
14. Jacobson IM McHutchison JG Dusheiko G: Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405-2416. 21696307 10.1056/NEJMoa1012912 F1000 Recommendation
15. Poordad F McCone J Jr Bacon BR: Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195-1206. 21449783 10.1056/NEJMoa1010494 3766849 F1000 Recommendation
16. Sherman KE Flamm SL Afdhal NH: Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011;365(11):1014-1024. 21916639 10.1056/NEJMoa1014463 3809077 F1000 Recommendation
17. Zeuzem S Andreone P Pol S: Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364(25):2417-2428. 21696308 10.1056/NEJMoa1013086 F1000 Recommendation
18. Hézode C Fontaine H Dorival C: Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology. 2014;147(1):132-142.e4. 24704719 10.1053/j.gastro.2014.03.051 F1000 Recommendation
19. Lok AS Gardiner DF Lawitz E: Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med. 2012;366(3):216-224. 22256805 10.1056/NEJMoa1104430 F1000 Recommendation
20. Afdhal N Reddy KR Nelson DR: Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483-1493. 24725238 10.1056/NEJMoa1316366 F1000 Recommendation
21. Afdhal N Zeuzem S Kwo P: Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889-1898. 24725239 10.1056/NEJMoa1402454 F1000 Recommendation
22. Lawitz E Matusow G DeJesus E: A phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve or -experienced patients with chronic HCV genotype 1 infection and cirrhosis: OPTIMIST-2. Journal of Hepatology. 2015.
23. Poordad F Hezode C Trinh R: ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370(21):1973-1982. 24725237 10.1056/NEJMoa1402869
24. Feld JJ Moreno C Trinh R: Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks. J Hepatol. 2016;64(2):301-307. 26476290 10.1016/j.jhep.2015.10.005
25. Bühler S Bartenschlager R: New targets for antiviral therapy of chronic hepatitis C. Liver Int. 2012;32(Suppl 1):9-16. 22212566 10.1111/j.1478-3231.2011.02701.x F1000 Recommendation
26. Feeney ER Chung RT: Antiviral treatment of hepatitis C. BMJ. 2014;348:g3308. 25002352 10.1136/bmj.g3308 F1000 Recommendation
27. Lupberger J Zeisel MB Xiao F: EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med. 2011;17(5):589-595. 21516087 10.1038/nm.2341 3938446 F1000 Recommendation
28. Janssen HL Reesink HW Lawitz EJ: Treatment of HCV infection by targeting microRNA. N Engl J Med. 2013;368(18):1685-1694. 23534542 10.1056/NEJMoa1209026 F1000 Recommendation
29. Bartenschlager R Lohmann V Penin F: The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat Rev Microbiol. 2013;11(7):482-496. 23748342 10.1038/nrmicro3046
30. Merz A Long G Hiet MS: Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome. J Biol Chem. 2011;286(4):3018-3032. 21056986 10.1074/jbc.M110.175018 3024796
31. Feld JJ Hoofnagle JH: Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature. 2005;436(7053):967-972. 16107837 10.1038/nature04082
32. Berger C Romero-Brey I Radujkovic D: Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication. Gastroenterology. 2014;147(5):1094-105.e25. 25046163 10.1053/j.gastro.2014.07.019
33. Jacobson IM Dore GJ Foster GR: Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2014;384(9941):403-413. 24907225 10.1016/S0140-6736(14)60494-3 F1000 Recommendation
34. Manns M Marcellin P Poordad F: Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2014;384(9941):414-426. 24907224 10.1016/S0140-6736(14)60538-9 F1000 Recommendation
35. Kowdley KV Lawitz E Crespo I: Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet. 2013;381(9883):2100-2107. 23499440 10.1016/S0140-6736(13)60247-0
36. Hézode C Hirschfield GM Ghesquiere W: Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut. 2015;64(6):948-956. 25080450 10.1136/gutjnl-2014-307498
37. Jensen D Sherman KE Hézode C: Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders. J Hepatol. 2015;63(1):30-37. 25703086 10.1016/j.jhep.2015.02.018
38. Zeuzem S Ghalib R Reddy KR: Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. Ann Intern Med. 2015;163(1):1-13. 25909356 10.7326/M15-0785 F1000 Recommendation
39. Jacobson IM Gordon SC Kowdley KV: Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368(20):1867-1877. 23607593 10.1056/NEJMoa1214854 F1000 Recommendation
40. Lawitz E Mangia A Wyles D: Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878-1887. 23607594 10.1056/NEJMoa1214853 F1000 Recommendation
41. Zeuzem S Dusheiko GM Salupere R: Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370(21):1993-2001. 24795201 10.1056/NEJMoa1316145 F1000 Recommendation
42. Sulkowski MS Gardiner DF Rodriguez-Torres M: Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370(3):211-221. 24428467 10.1056/NEJMoa1306218 F1000 Recommendation
43. Nelson DR Cooper JN Lalezari JP: All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61(4):1127-1135. 25614962 10.1002/hep.27726 4409820 F1000 Recommendation
44. Foster GR Pianko S Brown A: Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology. 2015;149(6):1462-1470. 26248087 10.1053/j.gastro.2015.07.043 F1000 Recommendation
45. Feld JJ Jacobson IM Hézode C: Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med. 2015;373(27):2599-2607. 26571066 10.1056/NEJMoa1512610 F1000 Recommendation
46. Saxena V Nyberg L Pauly M: Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C-Infected Patients With Compensated and Decompensated Cirrhosis. Hepatology. 2015;62(3):715-725. 26033798 10.1002/hep.27922 4549204 F1000 Recommendation
47. Al Marzooqi SH Feld JJ: Sorting out cirrhosis: mechanisms of non-response to hepatitis C therapy. Liver Int. 2015;35(8):1923-1933. 25939775 10.1111/liv.12861
48. Dyson JK Hutchinson J Harrison L: Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use. J Hepatol. 2016;64(1):234-238. 26325535 10.1016/j.jhep.2015.07.041
49. Welker MW Luhne S Lange CM: Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin/sofosbuvir treatment. J Hepatol. 2015; pii: S0168-8278(15)00792-8. 26658684 10.1016/j.jhep.2015.11.034
50. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm468757.htm. Reference Source
51. Sarrazin C: The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol. 2016;64(2):486-504. 26409317 10.1016/j.jhep.2015.09.011 F1000 Recommendation
52. Van Der Ree MH Vree JMD Stelma F: A single dose of RG-101, a GalNAc-Conjugated Oligonucleotide Targeting miR-122, Results in Undetectable HCV RNA Levels in Chronic Hepatitis C Patients at Week 28 of Follow-up. Hepatology. 2015;62((Van Der Ree MH, Stelma F, Willemse S, Van Der Valk M, Rietdijk S, Reesink HW) Gastroenterology and Hepatology, AMC, Amsterdam, Netherlands):315A-316A. Reference Source
53. Pawlotsky JM Flisiak R Sarin SK: Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection. Hepatology. 2015;62(4):1013-1023. 26118427 10.1002/hep.27960
54. Fauvelle C Felmlee DJ Crouchet E: Apolipoprotein E Mediates Evasion From Hepatitis C Virus Neutralizing Antibodies. Gastroenterology. 2016;150(1):206-217.e4. 26404951 10.1053/j.gastro.2015.09.014
55. Poynard T McHutchison J Manns M: Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002;122(5):1303-1313. 11984517 10.1053/gast.2002.33023 F1000 Recommendation
56. Shiratori Y Imazeki F Moriyama M: Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med. 2000;132(7):517-524. 10744587 10.7326/0003-4819-132-7-200004040-00002 F1000 Recommendation
57. Corpechot C Barbu V Wendum D: Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology. 2002;35(5):1010-1021. 11981751 10.1053/jhep.2002.32524
58. Desmet VJ Roskams T: Cirrhosis reversal: a duel between dogma and myth. J Hepatol. 2004;40(5):860-867. 15094237 10.1016/j.jhep.2004.03.007
59. Sherman IA Pappas SC Fisher MM: Hepatic microvascular changes associated with development of liver fibrosis and cirrhosis. Am J Physiol. 1990;258(2 Pt 2):H460-5. 2309911
60. D'Ambrosio R Aghemo A Rumi MG: A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology. 2012;56(2):532-543. 22271347 10.1002/hep.25606 F1000 Recommendation
61. van der Meer AJ Sonneveld MJ Schouten JN: [Reversibility of hepatic fibrosis]. Ned Tijdschr Geneeskd. 2014;158:A6790. 24594125
62. Veldt BJ Heathcote EJ Wedemeyer H: Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147(10):677-684. 18025443 10.7326/0003-4819-147-10-200711200-00003 F1000 Recommendation
63. Bruno S Stroffolini T Colombo M: Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology. 2007;45(3):579-587. 17326216 10.1002/hep.21492 F1000 Recommendation
64. Cardoso AC Moucari R Figueiredo-Mendes C: Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol. 2010;52(5):652-657. 20346533 10.1016/j.jhep.2009.12.028 F1000 Recommendation
65. Morgan TR Ghany MG Kim HY: Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010;52(3):833-844. 20564351 10.1002/hep.23744 2932862 F1000 Recommendation
66. Morgan RL Baack B Smith BD: Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013;158(5 Pt 1):329-337. 23460056 10.7326/0003-4819-158-5-201303050-00005 F1000 Recommendation
67. van der Meer AJ Veldt BJ Feld JJ: Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584-2593. 23268517 10.1001/jama.2012.144878
68. van der Meer AJ Feld JJ Hofer H: The risk for hepatocellular carcinoma among patients with chronic HCV infection and advanced hepatic fibrosis following sustained virological response. Hepatology. 2013;58(4):280A.
69. Spiegel BM Younossi ZM Hays RD: Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology. 2005;41(4):790-800. 15791608 10.1002/hep.20659
70. Arase Y Suzuki F Suzuki Y: Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology. 2009;49(3):739-744. 19127513 10.1002/hep.22703
71. Hsu YC Ho HJ Huang YT: Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut. 2015;64(3):495-503. 25398770 10.1136/gutjnl-2014-308163 F1000 Recommendation
72. Innes HA McDonald SA Dillon JF: Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes. Hepatology. 2015;62(2):355-364. 25716707 10.1002/hep.27766 F1000 Recommendation
73. Gragnani L Fognani E Piluso A: Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: a prospective, controlled, open-label, cohort study. Hepatology. 2015;61(4):1145-1153. 25431357 10.1002/hep.27623 F1000 Recommendation
74. Kawamura Y Ikeda K Arase Y: Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C. Am J Med. 2007;120(12):1034-1041. 18060923 10.1016/j.amjmed.2007.06.022
75. Berenguer J Rodríguez E Miralles P: Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus. Clin Infect Dis. 2012;55(5):728-736. 22610932 10.1093/cid/cis500
76. Backus LI Boothroyd DB Phillips BR: A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol. 2011;9(6):509-516.e1. 21397729 10.1016/j.cgh.2011.03.004 F1000 Recommendation
77. van der Meer AJ Wedemeyer H Feld JJ: Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population. JAMA. 2014;312(18):1927-1928. 25387192 10.1001/jama.2014.12627 F1000 Recommendation
78. Aleman S Rahbin N Weiland O: A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis. 2013;57(2):230-236. 23616492 10.1093/cid/cit234
79. Simmons B Saleem J Heath K: Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response. Clin Infect Dis. 2015;61(5):730-740. 25987643 10.1093/cid/civ396 4530725
80. Deterding K Höner Zu Siederdissen C Port K: Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies. Aliment Pharmacol Ther. 2015;42(7):889-901. 26250762 10.1111/apt.13343 F1000 Recommendation
81. Foster GR Irving WL Cheung MC: Cohort study of the impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016; pii: S0168-8278(16)00065-9. 26829205 10.1016/j.jhep.2016.01.029 F1000 Recommendation
82. Charlton M Gane E Manns MP: Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015;148(1):108-117. 25304641 10.1053/j.gastro.2014.10.001 F1000 Recommendation
83. Kwo PY Mantry PS Coakley E: An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014;371(25):2375-2382. 25386767 10.1056/NEJMoa1408921 F1000 Recommendation
84. Bourlière M Bronowicki JP de Ledinghen V: Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis. 2015;15(4):397-404. 25773757 10.1016/S1473-3099(15)70050-2 F1000 Recommendation
85. Dieterich D Bacon B Flamm S: P0775: Final evaluation of 955 HCV patients treated with 12 week regimens containing sofosbuvir +/- simeprevir in the trio network: Academic and community treatment of a real-world, heterogeneous population. J Hepatol. 2015;62(Supplement 2):S621. 10.1016/S0168-8278(15)30978-8
86. Jensen DM O'Leary JG Pockros PJ: Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: Real-world experience in a diverse, longitudinal observational cohort. Hepatology. 2014;60:219A-220A. Reference Source
87. Zeuzem S Ghalib R Reddy KR: Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. Ann Intern Med. 2015;163(1):1-13. 25909356 10.7326/M15-0785
88. Pearlman BL Ehleben C Perrys M: The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis. Gastroenterology. 2015;148(4):762-70.e2; quiz e11-2. 25557952 10.1053/j.gastro.2014.12.027
89. Aqel BA Pungpapong S Leise M: Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis. Hepatology. 2015;62(4):1004-1012. 26096332 10.1002/hep.27937 F1000 Recommendation
90. Shiffman ML James AM Long AG: Treatment of chronic HCV with sofosbuvir and simeprevir in patients with cirrhosis and contraindications to interferon and/or ribavirin. Am J Gastroenterol. 2015;110(8):1179-1185. 26215530 10.1038/ajg.2015.218
91. Poordad F Sievert W Mollison L: Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. JAMA. 2015;313(17):1728-1735. 25942723 10.1001/jama.2015.3860
92. Zeuzem S Dusheiko GM Salupere R: Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370(21):1993-2001. 24795201 10.1056/NEJMoa1316145
93. Foster GR Afdhal N Roberts SK: Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med. 2015;373(27):2608-2617. 26575258 10.1056/NEJMoa1512612
94. Leroy V Angus P Bronowicki JP: Daclatasvir, Sofosbuvir, and Ribavirin for Hepatitis C Virus Genotype 3 and Advanced Liver Disease: A Randomized Phase III Study (ALLY-3+). Hepatology. 2016. 26822022 10.1002/hep.28473
95. Manns M Forns X Samuel D: G02: Ledipasvir/sofosbuvir with ribavirin is safe and efficacious in decompensated and post liver transplantation patients with HCV infection: Preliminary results of the prospective solar 2 trial. J Hepatol. 2015;62(Supplement 2):S187-S188. 10.1016/S0168-8278(15)30003-9
96. Reddy R Lim JK Kuo A: O007: All oral HCV therapy is safe and effective in patients with decompensated cirrhosis: Interim report from the HCV-target real world experience. J Hepatol. 2015;62(Supplement 2):S193. 10.1016/S0168-8278(15)30014-3
97. Poordad F Schiff ER Vierling JM: Daclatasvir With Sofosbuvir and Ribavirin for HCV Infection With Advanced Cirrhosis or Post-Liver Transplant Recurrence. Hepatology. 2016. 26754432 10.1002/hep.28446
98. Backus LI Belperio PS Shahoumian TA: Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans. Aliment Pharmacol Ther. 2015;42(5):559-573. 26113432 10.1111/apt.13300 F1000 Recommendation
99. Curry MP O'Leary JG Bzowej N: Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med. 2015;373(27):2618-2628. 26569658 10.1056/NEJMoa1512614 F1000 Recommendation